Article focus {#section5-2046-3758.54.2000483}
=============

-   The induced membrane technique is gaining importance in current bone defect reconstruction.

-   However, limited information is available on the cell biology of the human biomembrane.

-   Objectives were to evaluate the cell biology and stem cell content of the biomembrane formed during the Masquelet technique applied to treatment of segmental bone loss.

Key messages {#section6-2046-3758.54.2000483}
============

-   Positive osteogenic differentiation was found in cells from biomembranes residing in the defect for six to 17 weeks.

-   Biomembrane morphology showed high vascularity and collagen content.

-   Biomembranes with longer maturation times showed upregulation of bone morphogenetic proteins, sonic hedgehog, and vascular and stem cell-related genes.

Strengths and limitations {#section7-2046-3758.54.2000483}
=========================

-   Although this study's sample size was limited to 13 patients, data presented help to advance the understanding of cellular and stem cell properties of the human biomembrane

-   Greater understanding of the biological properties of the biomembrane will facilitate development of methods to optimise bone defect reconstruction strategies.

-   Future research should focus on optimisation of osteogenic features of the cell population, and on ways to direct inherent stem cells towards the osteogenic lineage. These advances will help develop an optimal bone healing microenvironment.

Introduction {#section8-2046-3758.54.2000483}
============

High-energy trauma often produces complex limb injuries and large segmental bone defects. While several techniques have been employed to manage large bone defects, there is controversy regarding the optimal treatment.

One promising approach, the two-stage Masquelet technique (the polymethylmethacrylate (PMMA)-induced biomembrane or 'induced membrane'), has demonstrated moderate success in small clinical series.^[@bibr1-2046-3758.54.2000483][@bibr2-2046-3758.54.2000483][@bibr3-2046-3758.54.2000483][@bibr4-2046-3758.54.2000483][@bibr5-2046-3758.54.2000483][@bibr6-2046-3758.54.2000483][@bibr7-2046-3758.54.2000483][@bibr8-2046-3758.54.2000483][@bibr9-2046-3758.54.2000483][@bibr10-2046-3758.54.2000483][@bibr11-2046-3758.54.2000483][@bibr12-2046-3758.54.2000483][@bibr13-2046-3758.54.2000483]-[@bibr14-2046-3758.54.2000483]^ The first stage of the technique involves the development of an induced membrane layer of cells around surgically placed methacrylate spacers placed in a segmental bone defect. In the second stage, the spacers are removed, leaving behind the encasing biomembrane into which autologous cancellous bone grafts or other inductive and/or conductive materials may then be placed.

Few studies have attempted to characterise the biological properties of the human biomembrane,^[@bibr14-2046-3758.54.2000483]^ and the broad extent of its clinical potential in treatment of segmental bone defects remains to be fully explored. Aho et al^[@bibr14-2046-3758.54.2000483]^ examined histological properties of the biomembrane in 14 subjects and concluded that it consisted of mature vascularised fibrous tissue with some time-sensitive osteogenic and chondrogenic potential. The purpose of the present work was to evaluate the cell biology and stem cell content of the human biomembrane formed during the Masquelet technique for treatment of segmental bone loss. This study specifically explored the morphologic, stem cell, molecular and gene expression features. Improved understanding of the biological properties of the biomembrane will facilitate development of methods to optimise bone defect reconstruction strategies.

Materials and Methods {#section9-2046-3758.54.2000483}
=====================

This study was performed following Institutional Review Board approval. The need for informed consent was waived by the ethical board as the biomembrane tissue was sampled for tissue culture as part of routine surgical practice. Biomembrane tissue was harvested during the routine surgical removal of PMMA spacers in the second stage of the Masquelet technique performed by one of the senior authors (MJB) and transported to the laboratory in sterile media where it was subdivided for studies described below.

Histology and immunohistochemical analysis {#section10-2046-3758.54.2000483}
------------------------------------------

Biomembrane fragments were processed for routine histological studies using haematoxylin and eosin (H&E) and Masson trichrome staining. Trabecular bone was identified by direct visualisation at ×200 magnification, by two reviewers. Immunolocalisation for bone morphogenetic protein (BMP)2 and runt-related transcription factor (RUNX)2 used the anti-BMP2 antibody (Bioworld Technology, Inc., Saint Louis Park, Minnesota) at a 1:50 dilution and the anti-RUNX2 antibody (anti-RUNX2 monoclonal antibody, Abnova Corporation, Taipei, Taiwan) at a 1:100 dilution. Endogenous peroxidase was blocked using 3% H~2~O~2~ (Sigma-Aldrich, St Louis, Missouri). Universal Rabbit Negative Control and Mouse IgG (both Dako, Carpinteria, California) were used as negative controls for BMP2 and RUNX2, respectively. The secondary reagent was Vector ImmPRESS Reagent, Rabbit (Vector Laboratories Inc., Burlingame, California) for 30 minutes, followed by diaminobenzidine (DAB) (Dako) for five minutes. Slides were rinsed in water, counterstained with light green, dehydrated, cleared and mounted with resinous mounting media.

Cell differentiation analyses {#section11-2046-3758.54.2000483}
-----------------------------

Cells were cultured in monolayer from biomembrane fragments and used to test for stem cell potency using defined media, which allow differentiation to osteogenic, chondrogenic and adipogenic phenotypes using methods previously reported by our laboratory.^[@bibr15-2046-3758.54.2000483],[@bibr16-2046-3758.54.2000483]^ Differentiation of osteogenic cells was performed using the Osteogenesis Kit (Lonza Group AG, Basel, Switzerland)^[@bibr17-2046-3758.54.2000483]^ and assessed with positive alizarin red (Sigma-Aldrich) staining of mineralised matrix following 21 to 28 days of culture. Biomembrane cells were seeded at a density of 50 000 cells/well in a 24-well tissue culture plate, established in culture for between one and nine days, and then supplemented with the kit's Osteogenic Differentiation Media. Biomembrane cells were differentiated to adipogenic cells using the Mesenchymal Stem Cell Adipogenic Differentiation medium (Lonza); differentiated cells were stained with oil red O (Sigma-Aldrich) to demonstrate fat droplets.

Demonstration of chondrogenic differentiation was based on micromass *in vitro* formation by cells cultured for two to 18 days in Chondrogenic Induction Medium (Lonza), supplemented with 5% foetal bovine serum (FBS) and 10 ng/mL transforming growth factor-ß3 (TGF-β3). Cells were seeded at a density of 200 000 cells/well in a 24-well tissue culture plate and supplemented three times a week. Control cultures were supplemented with MSCBM (Mesenchymal Stem Cell Basal Medium, Lonza) basal media only. Control and differentiating cultures were supplemented three times per week. Digital images were used to document cell differentiations *in vitro*.

Human foetal osteoblast culture {#section12-2046-3758.54.2000483}
-------------------------------

The human osteoblast cell line hFOB 1.19 was obtained from the American Type Culture Collection (ATCC; Manassas, Virginia). Cells were grown in a 24-well tissue culture plate at 33.5° C, 95% humidity, and 5% CO~2~ with Dulbecco's Modified Eagle's Medium (DMEM)/Ham's F10 medium: 1:1 ratio DMEM/Ham's F12 with L-glutamine (DMEM/F12; Life Technologies, Carlsbad, California), 10% FBS (Atlas Biologicals, Fort Collins, Colorado), 0.3 mg/ml G418 (Geneticin R; Life Technologies). Once confluent, the growth medium was switched to differentiation media which consisted of DMEM/Ham's F10 with 0.1 mg/ml L-ascorbic acid, 10^−8^M menadione, 5 mM ß-glycerol phosphate, and 10^−7^M 1α,25-Dihydroxyvitamin D3 (Sigma-Aldrich). This differentiation methodology and this cell line have been previously described.^[@bibr18-2046-3758.54.2000483],[@bibr19-2046-3758.54.2000483]^ Cells were incubated at 39.5° C for seven days. To confirm osteoblast differentiation, wells were stained for bone mineralisation via alizarin red (data not shown).

Microarray gene expression studies {#section13-2046-3758.54.2000483}
----------------------------------

mRNA was harvested from biomembrane specimens following homogenisation; mRNA from the biomembrane and from cultured osteoblasts using Trizol (Life Technologies). Affymetrix microarray analyses were used to compare gene expression patterns of the biomembrane with cultured osteoblast cells (HG-U133 + PM strips; Affymetrix Inc., Santa Clara, California). Affymetrix '.cel' files were uploaded to GeneSifter web-based software (VizX Labs, Seattle, Washington), normalised, and statistical significance determined (p \< 0.05) using the unpaired student *t*-test (two-tailed). Data were corrected for false discovery rates using the Benjamini-Hochberg test and results are expressed as fold changes (2.0 and greater only). Ontology searches (which allow one to avoid searching gene by gene and also provide a controlled vocabulary of search terms for gene characteristics) were used for the following bone-related ontology groupings: angiogenesis and related vascularity categories; collagen; bone development; bone remodeling; negative regulation of bone remodeling; positive regulation of bone remodeling; regulation of bone remodeling; bone resorption; BMP signaling pathway; ossification; regulation of osteoblast differentiation; positive regulation of osteoblast differentiation; osteoblast differentiation; osteoblast development; negative regulation of osteoclast differentiation; positive regulation of osteoclast differentiation; regulation of osteoclast differentiation; osteoclast differentiation; chondrocyte differentiation; chondrocyte development; cartilage development, and the following ontologies for stem cells: differentiation, division, regulation of stem cell division, maintenance, and canonical WNT receptor signaling pathway involved in mesenchymal stem cell differentiation.

An additional analysis of gene expression patterns was carried out, which used the ontology groups described above to test for differences in major bone-, cartilage- and vascular-related genes in specimens with longer spacer duration periods (\> 12 weeks) *versus* specimens with shorter spacer durations.

Statistical analysis {#section14-2046-3758.54.2000483}
--------------------

For non-microarray data analysis, standard statistical methods were used employing InStat (GraphPad Software, Inc., San Diego, California). Means and standard deviation ([sd]{.smallcaps}) were calculated, and p \< 0.05 was set as the significance level. Spearman's correlation was used to test for linear relationships between the presence (scored as one) or absence (scored as two) of trabecular bone within the biomembrane histological specimen and the duration of the PMMA spacer in the surgical site.

Results {#section15-2046-3758.54.2000483}
=======

Subjects {#section16-2046-3758.54.2000483}
--------

Demographic and clinical features of the study population are presented in [Table I](#table1-2046-3758.54.2000483){ref-type="table"}. Biomembrane specimens were obtained from 12 surgeries for complex fractures (mean age 40.7 years, [sd]{.smallcaps} 14.4; four women, eight men) resulting from six motor vehicle or motorcycle accidents, four falls, and two gunshot wounds. [Table I](#table1-2046-3758.54.2000483){ref-type="table"} presents data on the surgical site, low- or high-energy causes for the trauma, the presence or absence of infection, the length of the bony defect, the volume of the PMMA spacer, and Arbeitsgemeinschaft für Osteosynthesefragen/American Orthopaedic Trauma Association (AO/OTA) classification^[@bibr20-2046-3758.54.2000483]^ and the Gustilo classification.^[@bibr21-2046-3758.54.2000483]^ The mean duration of the PMMA spacers within the patient fracture sites was 11.9 weeks (six to 18). Radiographic measurements (in cm) were performed using AP and lateral radiographs of fractures at the time of fixation during PMMA spacer placement. Lengths, widths and depths were obtained and data used to calculate the approximate PMMA spacer volume (in cm^3^) ([Table I](#table1-2046-3758.54.2000483){ref-type="table"}). In total, 50% of the subjects had bone infections at the time of PMMA spacer placement ([Table I](#table1-2046-3758.54.2000483){ref-type="table"}).

###### 

Demographic and clinical features of study population.^[\*](#table-fn2-2046-3758.54.2000483){ref-type="table-fn"}^

  Age (yrs)/gender   Fracture location                                                          Cause of trauma                                                  AO/OTA class-ification   Gustilo class-ification   Fracture fixation during cement spacer   Bone infection (Y/N)   Bony defect length (cm)^[\*](#table-fn2-2046-3758.54.2000483){ref-type="table-fn"}^   Volume of PMMA spacer (cm^3^)   Duration (weeks) of spacer in site   Experimental studies performed
  ------------------ -------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------ ------------------------- ---------------------------------------- ---------------------- ------------------------------------------------------------------------------------- ------------------------------- ------------------------------------ --------------------------------
  18/F               Distal tibia                                                               Vehicle crash into tree                                          43-A3                    3A                        ORIF tibia                               N                      5                                                                                     23                              6                                    H, O, C, A, G
  59/M               Distal femur^[\*](#table-fn2-2046-3758.54.2000483){ref-type="table-fn"}^   Low-energy fall (fell while standing; periprosthetic fracture)   33-A3                    N/A                       ORIF distal femur                        Y                      12                                                                                    293                             6                                    H, O, C, A, G
  33/F               Distal femur                                                               Motorcycle/vehicle accident                                      33-C3                    3A                        ORIF distal femur                        N                      10                                                                                    220                             7                                    H, O, C, A, G
  28/M               Diaphyseal femur                                                           GSW                                                              32-C3                    3A                        IM nail femur                            Y                      8                                                                                     185                             9                                    H, O, C, A, G
  48/F               Distal tibia                                                               MVC                                                              43-C3                    3B                        ORIF distal tibia/IM fixation fibula     N                      9                                                                                     80                              9                                    H, O, C, A, G
  56/M               Distal tibia                                                               Low energy fall (fell from stool)                                43-A3                    2                         Ilizarov external fixation tibia         Y                      6                                                                                     57                              11                                   H, O, C, A, G
  52/M               Distal tibia                                                               Fell out of vehicle and hit by following vehicle                 43-A3                    3B                        IM nail tibia                            N                      6                                                                                     17                              13                                   H, C, G
  27/F               Distal tibia                                                               MVC                                                              43-C3                    3B                        External fixation and ORIF fibula        Y                      4                                                                                     37                              15                                   H, O, C, A, G
  42/M               Diaphyseal tibia                                                           Motorcycle/vehicle accident                                      42-C2                    3B                        IM nail tibia                            N                      13                                                                                    141                             16                                   H, G
  62/M               Distal tibia                                                               Crush injury (tree limb fell on leg)                             43-A3                    3B                        External fixation tibia                  Y                      7                                                                                     49                              16                                   H, O, C, A, G
  30/M               Diaphyseal tibia                                                           GSW                                                              42-C3                    3A                        Ilizarov external fixation tibia         N                      14                                                                                    112                             17                                   H, O, C, A, G
  34/M               Distal tibia                                                               High-energy fall (jumped from balcony)                           43-C2                    3B                        ORIF tibia/fibula                        Y                      7                                                                                     84                              18                                   H, O, C, A

PMMA, polymethylmethacrylate; M, male; F, female; MVC, motor vehicle collision; GSW, gunshot wound, H, histology and immunohistochemistry; O, osteogenesis determination; C, chondrogenesis; A, adipogenesis determination; G, microarray gene expression analysis; AO/OTA, Arbeitsgemeinschaft für Osteosynthesefragen/American Orthopaedic Trauma Association; ORIF, open reduction and internal fixation; IM, intramedullary

Closed fracture (all other cases were open)

Morphological features of the human biomembrane {#section17-2046-3758.54.2000483}
-----------------------------------------------

Biomembrane tissues examined with routine histology showed the presence of trabecular bone in four out of 12 (33.3%) of the biomembrane specimens ([Fig. 1](#fig1-2046-3758.54.2000483){ref-type="fig"}). There was no correlation between the presence of trabecular bone in the specimens and the duration of the PMMA spacer in the surgical site. Morphological analysis showed the presence of high collagen content and extensive vascularity ([Fig. 2](#fig2-2046-3758.54.2000483){ref-type="fig"}). Immunohistochemistry showed that the osteoinductive factor BMP2 was present in osteoblasts, osteocytes and in cells within the biomembrane stroma ([Fig. 3](#fig3-2046-3758.54.2000483){ref-type="fig"}). RUNX2 (also called CBFA1, a regulator of osteoblast differentiation) was also found to be present within the biomembrane ([Fig. 4](#fig4-2046-3758.54.2000483){ref-type="fig"}).

![Light microscopic features of the biomembrane tissue. Trabecular bone (arrow) was present in 4/13 (33.3%) of specimens examined for morphological features. (Masson trichrome stain; bar = 50 µm).](bonejointres-05-106-g001){#fig1-2046-3758.54.2000483}

![Light microscopy showing the highly vascular nature of the biomembrane. Arrows mark vasculature. (Masson trichrome stain; bar = 50 µm).](bonejointres-05-106-g002){#fig2-2046-3758.54.2000483}

![Immunohistochemical localisation of bone morphogenetic protein 2 in the biomembrane. Insert upper right shows an adjacent section processed as a negative control (Bar = 50 µm).](bonejointres-05-106-g003){#fig3-2046-3758.54.2000483}

![Immunohistochemical localisation of runt-related transcription factor 2 within the biomembrane. Insert upper right shows an adjacent section processed as a negative control (Bar = 20 µm).](bonejointres-05-106-g004){#fig4-2046-3758.54.2000483}

Stem cell capacity of the biomembrane {#section18-2046-3758.54.2000483}
-------------------------------------

Cells cultured from the biomembrane grew well and displayed a spindle-shaped morphology in monolayer culture. Positive osteogenic capacity was demonstrated in seven out of ten (70%) tested cultures ([Fig. 5](#fig5-2046-3758.54.2000483){ref-type="fig"}). Chondrogenic capacity was demonstrated by formation of micromasses ([Fig. 6](#fig6-2046-3758.54.2000483){ref-type="fig"}) with the strong presence of chondroitin sulfate on immunohistochemistry ([Fig. 7](#fig7-2046-3758.54.2000483){ref-type="fig"}). Chondrogenic differentiation was seen in 90.9% of specimens (11 out of 12 tested specimens). Adipogenic differentiation was demonstrated by the presence of fat droplets ([Fig. 8](#fig8-2046-3758.54.2000483){ref-type="fig"}). Adipogenic differentiation was seen in 90% of the specimens (nine out of ten tested specimens). Additional data were gained on the stem cell features of the biomembrane by microarray analyses which compared the biomembrane to cultured osteoblasts ([Table II](#table2-2046-3758.54.2000483){ref-type="table"}). Gene expression was stronger in the biomembrane for secreted frizzled-related protein (SFRP) 2 (upregulated 77 fold), an important factor which interacts with Wnt signaling to enhance mesenchymal stem cell engraftment and myocardial repair.^[@bibr22-2046-3758.54.2000483],[@bibr23-2046-3758.54.2000483]^

![Biomembrane cells cultured in osteogenic differentiation media showed development of calcified nodules as verified here with alizarin red staining. Insert lower right shows no development of calcified nodules in cells grown in control medium. Original magnification ×200.)](bonejointres-05-106-g005){#fig5-2046-3758.54.2000483}

![Biomembrane cells cultured in chondrogenesis media showed the formation of compact micromasses *in vitro* (diameter of the culture plate well shown is 16 mm).](bonejointres-05-106-g006){#fig6-2046-3758.54.2000483}

![Micromass specimen embedded in paraffin and processed for immunohistochemical localisation of chondroitin sulfate. Note the abundant presence of this matrix component. Insert upper right shows an adjacent section processed as a negative control (Bar = 20 µm).](bonejointres-05-106-g007){#fig7-2046-3758.54.2000483}

![Biomembrane cells cultured for adipogenesis show the presence of fat droplets (stained red in the micrograph). Insert lower right shows that biomembrane cells cultured in control media showed no presence of fat droplets (original magnification ×200).](bonejointres-05-106-g008){#fig8-2046-3758.54.2000483}

###### 

Major bone-, cartilage- and vascular-related gene expression findings in biomembrane specimens *vs* osteoblast cells.

  Gene name                                               Direction   Fold change   p-value     Gene identifier   Gen ID
  ------------------------------------------------------- ----------- ------------- ----------- ----------------- ---------
  **Stem cell-related genes**                                                                                     
  Fibroblast-like growth factor 2 (basic)                 Down        45.8          \< 0.0001   NM_002006         FGF2
  Notch homolog 2                                         Down        2.6           0.001       AF308601          Notch2
  Transforming growth factor, beta 2                      Down        27.2          \< 0.0001   M19154            TGF-β2
  Wingless-type MMTV integration site family, member 3    Down        7.2           \< 0.0001   AA463626          WNT3
  Wingless-type MMTV integration site family, member 5A   Down        40.9          0.0002      NM_003392         WNT5A
  Insulin-like growth factor 1 (somatomedin C)            Up          30.7          0.0001      AU44912           IGF1
  Secreted frizzled-related protein 2                     Up          77.7          \< 0.0001   AF11912           SFRP2N
  **Bone or cartilage-related genes**                                                                             
  Bone gamma-carboxyglutamate (gla) protein               Down        29.1          \< 0.0001   NM_000711         BGLAP
  Cyclin-dependent kinase 6                               Down        4.3           0.04        AW274756          CDK6
  Fibrillin 2                                             Down        21.3          0.0009      NM-001999         FBN2
  Interleukin 6                                           Down        22.5          0.0002      NM_000600         IL-6
  SATB homeobox 2                                         Down        3.5           0.013       AB028957          SATB2
  Tumour necrosis factor, alpha-induced protein 3         Down        2.6           0.04        AI738896          TNFAIP3
  Acid phosphatase 5, tartrate resistant                  Up          5.0           0.01        NM_001611         ACP5
  Asporin                                                 Up          208.6         \< 0.0001   NM_017680         ASPN
  Biglycan                                                Up          16.9          0.03        AA845258          BGN
  Bone morphogenetic protein 2                            Up          3.6           0.003       NM_001200         BMP2
  Bone morphogenetic protein 6                            Up          2.1           0.009       NM_0017_PM_at     BMP6
  Chemokine (C-C motif) ligand 5                          Up          4.2           0.006       NM_002985         CCL5
  Collagen, type I, alpha 2                               Up          3.7           0.006       AA628535          COL1A2
  Collagen, type III, alpha 1                             Up          4.5           0.02        AU146808          COL3A1
  Collagen, type V, alpha 3                               Up          9.9           0.001       AI984221          COL5A3
  Collagen, type VI, alpha 2                              Up          2.8           0.04        AL531750          COL6A2
  Collagen, type VIII, alpha 1                            Up          7.0           0.008       AI806793          CO:8A2
  Collagen, type XI, alpha 1                              Up          11.1          0.003       J04177            COL11A1
  Collagen, type XII, alpha 1                             Up          11.0          0.006       AU146651          COL12A1
  Collagen, type XIV, alpha 1                             Up          27.8          0.001       BF449063          COL14A1
  Decorin                                                 Up          7.7           0.0003      AI281593          DCN
  Growth hormone receptor                                 Up          4.9           0.04        NM_000163         GHR
  Interleukin 23, alpha subunit p19                       Up          4.6           0.005       AL559122          IL23A
  Matrix Gla protein                                      Up          158.4         \< 0.0001   NM_0009000        MGP
  Matrix metallopeptidase 14                              Up          2.5           0.004       Z48481            MMP14
  Matrix metallopeptidase 9 (type IV collagenase)         Up          12.0          0.01        NM_004994         MMP9
  Runt-related transcription factor 2                     Up          6.2           0.0005      AW469546          RUNX2
  **Vascular-related genes**                                                                                      
  Angiopoietin 1                                          Down        2.6           0.003       U83508            ANGPT1
  BMP binding endothelial regulator                       Down        5.0           \< 0.0001   AI423201          BMPER
  Bradykinin receptor B2                                  Down        5.5           0.0003      NM_000623         BDKRB2
  Endothelin 1                                            Down        2.4           0.03        J05008            EDN1
  Vascular endothelial growth factor A                    Down        2.1           0.004       M272781           VEGFA
  Vascular endothelial growth factor C                    Down        8.8           0.005       U58111            VEGFC
  Vasohibin 2                                             Down        15.0          \< 0.0001   AI961235          VASH2
  Angiogenin, RNase A family, 5                           Up          5.6           0.01        AI761728          ANG
  Angiopoietin 2                                          Up          12.7          0.001       AA0835514         ANGPT2
  Aquaporin 1                                             Up          34.2          0.0003      AL518391          AQP1
  Endothelial cell-specific chemotaxis regulator          Up          5.6           0.01        AI422211          ECSCR
  Endothelin receptor type B                              Up          3.1           0.002       NM_003991         EDNRB

Molecular characterisation of bone-, cartilage- and vasculature-related gene expression: comparison of biomembrane expression patterns with osteoblast cell culture {#section19-2046-3758.54.2000483}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table II](#table2-2046-3758.54.2000483){ref-type="table"} shows findings regarding the upregulation of genes in the biomembrane (in comparison with expression patterns in cultured osteoblasts) for genes related to bone and cartilage (BMP2, upregulated three-fold; BMP6, upregulated three-fold; matrix gla protein, upregulated 158-fold; and RUNX2, upregulated six-fold), and many collagen genes, including collagen type I, alpha 2. Also present were several genes related to vasculature with strong expression patterns, including angiopoietin 2 (upregulated 12-fold), and endothelial cell-specific chemotaxis regulator (upregulated five-fold).

Comparison of biomembranes with longer *versus* shorter PMMA spacer residence {#section20-2046-3758.54.2000483}
-----------------------------------------------------------------------------

The second type of gene analysis performed was a comparison of genes expressed in biomembranes in spacers that resided within the host subject for \> 12 weeks compared with those from spacers that had a duration of \< 12 weeks ([Table III](#table3-2046-3758.54.2000483){ref-type="table"}). For spacers with longer maturation times, it was noted that there remained a modest upregulation of several genes with recognised relationships to stem cells (BMP7, MYST histone acetyltransferase 3, fibroblast growth factor (FGF) receptors 1 and 2, FGF 4 and sonic hedgehog). With respect to bone- and cartilage-related genes, upregulation was seen in oestrogen receptor 1 (upregulated 3.1-fold), growth and differentiation factor 5 (upregulated 2.4-fold) and a number of matrix-related genes.

###### 

Major bone-, cartilage- and vascular-related gene expression findings in human biomembrane specimens with longer spacer duration (\> 12 weeks) *versus* those with shorter duration.

  Gene name                                                   Direction   Fold change   p-value    Gene identifier   Gen ID
  ----------------------------------------------------------- ----------- ------------- ---------- ----------------- ------------
  **Stem cell-related genes**                                                                                        
  Frizzled homolog 1 (Drosophila)                             Down        4.54          0.02       NM_003505         FZD1
  Frizzled homolog 7 (Drosophila)                             Down        2.89          0.039      AI333651          FZD7
  Insulin-like growth factor 1 (somatomedin C)                Down        2.27          0.037      M29644            IGF1
  MYST histone acetyltransferase 3                            Down        5.46          0.009      AI817830          MYST3
  Notch homolog 2                                             Down        3.36          0.03       AU158495          Notch2
  Secreted frizzled-related protein 2                         Down        6.32          0.026      AW003584          SFRP2
  Wingless-type MMTV integration site family, member 3        Down        7.2           \<0.0001   AA463626          WNT3
  Bone morphogenetic protein 7                                Up          2.03          0.009      M60316            BMP7
  Fibroblast growth factor receptor 1                         Up          2.14          0.009      NM_023110         FGFR1
  Fibroblast growth factor receptor 2                         Up          3.23          0.009      AB030073          FGFR2
  Fibroblast growth factor 4                                  Up          3.04          0.01       NM_002007         FGF4
  Sonic hedgehog homolog (drosophila)                         Up          2.42          0.01       AI92528           SHH
  **Bone or cartilage-related genes**                                                                                
  ADAM metallopeptidase domain 9 (meltrin gamma)              Down        6.65          0.009      NM_003816         ADAM9
  ADAM metallopeptidase with thrombospondin type 1 motif, 3   Down        2.53          0.015      AB002364          ADAMTS3
  Bone morphogenetic protein receptor, type IA                Down        4.26          0.013      AI678679          BMPR1A
  Bone morphogenetic protein receptor, type II                Down        6.4           0.009      AL046696          BMPR2
  Cartilage-associated protein                                Down        2.49          0.023      AW024741          CRTAP
  Chondroitin sulfate N-acetyl-galactosaminyltransferase 1    Down        10.28         0.009      NM_018371         CSGALNACT1
  Chondroitin sulfate N-acetyl galactosaminyltransferase 2    Down        3.36          0.016      NM_018590         CSGALNACT2
  Chondroitin sulfate synthase 1                              Down        5.21          0.011      NM_014918         CHSY1
  Collagen type I, alpha 1                                    Down        3.33          0.026      AI743621          COL1A1
  Collagen, type I, alpha 2                                   Down        2.38          0.011      AA62835           COL1A2
  Collagen, type III, alpha 1                                 Down        3.69          0.010      AU144167          COL3A1
  Collagen, type V, alpha 1                                   Down        5.34          0.020      AI130969          COL5A1
  Collagen, type V, alpha 3                                   Down        3.09          0.009      AI984221          COL5A3
  Collagen, type VI, alpha 1                                  Down        2.98          0.047      AA292373          COL6A1
  Collagen, type VI, alpha 2                                  Down        2.54          0.009      AL531750          COL6A2
  Decorin                                                     Down        4.35          0.011      NM_001920         DCN
  Dystroglycan 1                                              Down        4.12          0.012      NM_004393         DAG1
  Fibroblast growth factor receptor 1                         Down        3.19          0.012      M60485            FGFR1
  Growth hormone receptor                                     Down        4.21          0.011      NM_000163         GHR
  Heparan sulfate 2-O-sulfotransferase 1                      Down        4.31          0.011      NM_012262         HS2ST1
  Hypoxia inducible factor 1, alpha subunit                   Down        3.72          0.012      NM_001530         HIF1A
  Insulin-like growth factor 1 (somatomedin C)                Down        2.27          0.039      M29644            IGF1
  Insulin-like growth factor binding protein 3                Down        5.5           0.015      BF340228          IGFBP3
  Insulin-like growth factor binding protein 5                Down        2.83          0.047      AW007532          IGFBP5
  Interleukin 6 signal transducer                             Down        7.07          0.009      AW242916          IL6ST
  Matrilin 2                                                  Down        4.71          0.049      NM_002380         MATN2
  Matrix Gla protein                                          Down        3.55          0.013      AW512787          MGP
  Matrix metallopeptidase 2                                   Down        2.66          0.039      NM_004530         MMP2
  Matrix metallopeptidase 9                                   Down        4.37          0.030      NM_004994         MMP9
  Matrix metallopeptidase 13 (collagenase 3)                  Down        4.13          0.024      NM_002427         MMP13
  Osteoglycin                                                 Down        4.07          0.042      NM_014057         OGN
  Osteoclast stimulating factor 1                             Down        4.46          0.009      NM_012383         OSTF1
  Periostin, osteoblast specific factor                       Down        4.65          0.034      AW137148          POSTN
  Runt-related transcription factor 2                         Down        4.47          0.012      AL353944          RUNX2
  SMAD family member 1                                        Down        7.26          0.009      U54826            SMAD1
  Sulfatase 2                                                 Down        3.69          0.012      AL133001          SULF2
  Tenascin C                                                  Down        7.85          0.016      NM_002160         TNC
  Thyroid hormone receptor, beta                              Down        3.22          0.019      BG494007          THRB
  TIMP metallopeptidase inhibitor 2                           Down        3.4           0.01       NM_003255         TIMP2
  Transforming growth factor, beta 3                          Down        2.17          0.011      J03241            TGF-β3
  Tumour necrosis factor, alpha-induced protein 3             Down        3.22          0.009      NM_006290         TNFAIP3
  Versican                                                    Down        9.07          0.011      D32029            VCAN
  Vitamin D receptor                                          Down        3.12          0.009      NM_000376         VDR
  ADAM metallopeptidase with thrombospondin type 1 motif, 9   Up          3.3           0.009      AB037733          ADAMTS9
  Aggrecan                                                    Up          3.9           0.009      BC036445          ACAN
  Bone morphogenetic protein 7                                Up          2.03          0.009      M60316            BMP7
  Bone morphogenetic protein 10                               Up          2.04          0.019      NM_014482         BMP10
  Epidermal growth factor receptor                            Up          4.69          0.01       AF277897          EGFR
  Estrogen receptor 1                                         Up          3.13          0.009      AF258450          ESR1
  Fibrillin 2                                                 Up          2.63          0.009      AF193046          FBN2
  Fibroblast growth factor 4                                  Up          3.04          0.01       NM_002007         FGF4
  Fibroblast growth factor receptor 2                         Up          3.23          0.009      AB030073          FGFR2
  Growth differentiation factor 5                             Up          2.4           0.009      NM_000557         GDF5
  G protein-coupled receptor 55                               Up          2.48          0.027      NM_005683         GPR55
  Heparan sulfate (glucosamine) 3-O-sulfotransferase 5        Up          2.43          0.011      AW449310          HS3ST5
  Hyaluronan and proteoglycan link protein 4                  Up          2.59          0.009      W63783            HAPLN4
  Interleukin 21                                              Up          2.26          0.012      NM_021803         IL21
  Interleukin 23, alpha subunit p19                           Up          2.86          0.013      AJ296370          IL23A
  Natriuretic peptide receptor C/guanylate cyclase C          Up          2.35          0.009      AI628360          NPR3
  Retinoic acid receptor, gamma                               Up          2.32          0.011      M57707            RARG
  Sonic hedgehog homolog (Drosophila)                         Up          2.42          0.01       AI192528          SHH
  Tenascin R                                                  Up          2.23          0.009      Y13359            TNR
  Thrombospondin 1                                            Up          2.65          0.013      BF084105          THBS1
  **Vascular-related genes**                                                                                         
  Angiopoietin 1                                              Down        3.36          0.012      NM_001146         ANGPT1
  Angiopoietin 2                                              Down        6.28          0.01       NM_001147         ANGPT2
  Aquaporin 1                                                 Down        3.7           0.011      AL518391          AQP1
  Lysyl oxidase                                               Down        5.01          0.013      NM_002317         LOX
  Endothelin 1                                                Down        2.76          0.01       NM_001955         EDN1
  Endothelial cell-specific chemotaxis regulator              Down        5.13          0.009      AI422211          ECSCR
  Endothelin receptor type A                                  Down        6.09          0.009      AU118882          EDNRA
  Vascular endothelial growth factor A                        Down        7.33          0.017      AF022375          VEGFA
  Angiopoietin-like 3                                         Up          2.21          0.009      AV659209          ANGPTL3
  Angiopoietin 4                                              Up          2.33          0.012      NM_015985         ANGPT4
  Endoglin                                                    Up          2.08          0.009      AA906156          ENG
  Epiregulin                                                  Up          2.45          0.009      BC03506           EREG
  Vasohibin 2                                                 Up          2.7           0.01       BC028194          --

Discussion {#section21-2046-3758.54.2000483}
==========

The ability to reconstruct large bone defects that occur as a result of open fractures and/or infections remains a significant challenge in orthopaedic trauma. The Masquelet technique, which uses an induced biomembrane as a conduit for bone graft, has increasingly been used in treatment of patients with complicated segmental bone loss. The purpose of this study was to investigate the cell biology and stem cell content of the human biomembrane formed during the induced biomembrane technique.

Our results demonstrated that the histological presence of isolated bone islands formed with the biomembrane tissue harvested at the time of spacer removal was consistent with intramembranous ossification. This is an important finding in human biomembrane research and is similar to previous studies from our laboratory that have evaluated the properties of biomembranes formed in a rat segmental defect model.^[@bibr24-2046-3758.54.2000483],[@bibr25-2046-3758.54.2000483]^

Stem cell differentiation analyses in the current study used cells isolated from the human biomembrane. These cells showed a greater variability in pluripotency for osteogenic potential (70%) compared with chondrogenic or adipogenic potentials (100% and 90%, respectively). Since the clinical outcome desired with the Masquelet approach is bone formation, we chose an osteoblast cell line rather than fibroblasts for comparison with the biomembrane in our gene expression analyses as osteoblasts are more relevant to expression patterns related to bone formation. Strong expression and high fold changes were found for bone-, cartilage-, stem cell- and angiogenesis-related genes ([Table II](#table2-2046-3758.54.2000483){ref-type="table"}).^[@bibr22-2046-3758.54.2000483],[@bibr23-2046-3758.54.2000483]^ The high expression level of asporin (upregulated 208 times) merits comment. As shown in previous osteoarthritis literature, not only can this extracellular matrix protein inhibit TGF-ß and regulate chondrogenic potential with additional evidence for a role in osteoarthritis,^[@bibr26-2046-3758.54.2000483],[@bibr27-2046-3758.54.2000483]^ but also, some research points to elevated asporin expression in osteoblasts in subchondral bone in osteoarthritic patients.^[@bibr28-2046-3758.54.2000483]^ In the second part of our gene analysis studies, we looked for differences in expression patterns in PMMA spacers with longer *versus* shorter maturation periods. Upregulation of several stem cell-related genes was identified as well as bone-, cartilage- and vascular-related genes ([Table III](#table3-2046-3758.54.2000483){ref-type="table"}). Downregulation of several genes was also seen. We would postulate that this is because these genes, including type I collagen, were more actively expressed in the early biomembrane stages during formation of the stroma and islands of trabecular bone.

The biomembrane lies within a highly complex biological milieu in which many cytokine systems are active.^[@bibr29-2046-3758.54.2000483][@bibr30-2046-3758.54.2000483]-[@bibr31-2046-3758.54.2000483]^ The biomembrane is used clinically as both a receptive bed for bone formation and a source of mesenchymal stem cells which may be recruited and directed to this bed during the healing process. Although several small animal models have been used to evaluate the biomembrane, few studies have analysed the cellular features and stem cell content of biomembranes isolated from humans. A recent paper by Aho et al^[@bibr14-2046-3758.54.2000483]^ analysed properties of the induced biomembrane from 14 human subjects. They concluded that the biomembrane consisted of mature vascularised fibrous tissue with some osteogenic and chondrogenic time-sensitive potential. However, unlike the current study, their work did not extensively evaluate the difference in gene expression patterns of several bone-, cartilage- and vascular-related genes. The gene expression work reported in the present study may serve as a foundation for future studies that focus on specific gene up- or down-regulation in order to optimise the biomembrane osteogenic potential.

This study has several strengths and limitations. One strength is that data presented herein are shown in relation to well characterised clinical findings, including PMMA spacer duration, energy levels of the trauma source, AO/OTA and Gustilo classifications, fracture fixation descriptions, presence or absence of infection, and measurements of bone defect lengths and volume of the PMMA spacer ([Table I](#table1-2046-3758.54.2000483){ref-type="table"}). One other important consideration and possible limitation of this study is that the biomembrane analyses presented here are based upon specimens derived from variable sites in the tibia and femur, and the biomembranes formed in response to variable PMMA spacer sizes which resided in the site for different time periods (six to 18 weeks). There was also significant variation in subject ages (18 to 62 years). These factors undoubtedly influenced important features such as vascularisation since the vascularity and healing potential in a younger subject would presumably be greater than that of a middle-aged subject. However, this variability in study population structure reflects the potential age range of trauma patients with severe large bone defects who may be effectively treated with the Masquelet technique. Results from age- and site-controlled small animal studies were previously reported by our group.^[@bibr24-2046-3758.54.2000483],[@bibr25-2046-3758.54.2000483]^ Another limitation of this study is that it has a relatively small sample size for the gene expression analyses. Although many of the differences in gene expression reached statistical significance, future studies with larger sample sizes are needed.

Our findings add additional clinical cases to the literature, and advance this research by quantifying the osteogenic, chondrogenic and adipogenic differentiation potential of cells within the biomembrane. This novel work establishes baseline data for the process during which biomembrane cells differentiate into important stem cells. We look forward to such information being used in work designed to optimise the osteogenic or chondrogenic potential of the biomembrane, potentially expediting the timeline for healing segmental bone defects in patients with complex fractures.

In conclusion, the Masquelet technique (PMMA-induced biomembrane) is successfully employed in current bone defect reconstruction treatment. Limited data exist on detailed characterisation of the cell biology of the human biomembrane. We suggest that future research directed towards optimising the biological features of the biomembrane should focus on optimisation of the osteogenic features of the cell population and on ways to direct the stem cells present in the biomembrane into the osteogenic lineage (25% of our biomembrane cell specimens did not differentiate into osteoblasts). This is vital since timely formation of high-quality bone is of paramount importance in the clinical patient population with segmental bone defects. The work presented herein represents an important step forward in the advancement of our understanding of the cellular features and stem cell properties of the human biomembrane and highlights the importance for future research in which biomembranes may be modified to create an optimal bone healing microenvironment.
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